Display options
Cite
Ferrucci PF, Pala L, Conforti F, et al. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061383.
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13(6), . https://doi.org/10.3390/cancers13061383
Ferrucci, Pier Francesco, et al. "Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061383
Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel). 2021 Mar 18;13(6). doi: 10.3390/cancers13061383. PMID: 33803762; PMCID: PMC8003308.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Mar 18;13(6). doi: 10.3390/cancers13061383.

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.

Cancers

Pier Francesco Ferrucci, Laura Pala, Fabio Conforti, Emilia Cocorocchio

Affiliations

  1. Tumor Biotherapy Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
  2. Division of Melanoma, Sarcoma and Rare Tumors, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
  3. Hemato-Oncology Division, European Institute of Oncology, IRCCS, 20141 Milan, Italy.

PMID: 33803762 PMCID: PMC8003308 DOI: 10.3390/cancers13061383

Abstract

Direct intralesional injection of specific or even generic agents, has been proposed over the years as cancer immunotherapy, in order to treat cutaneous or subcutaneous metastasis. Such treatments usually induce an effective control of disease in injected lesions, but only occasionally were able to demonstrate a systemic abscopal effect on distant metastases. The usual availability of tissue for basic and translational research is a plus in utilizing this approach, which has been used in primis for the treatment of locally advanced melanoma. Melanoma is an immunogenic tumor that could often spread superficially causing in-transit metastasis and involving draining lymph nodes, being an interesting model to study new drugs with different modality of administration from normal available routes. Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for intratumoral injection, that produces granulocyte-macrophage colony-stimulating factor (GM-CSF) and enhances local and systemic antitumor immune responses. After infection, selected viral replication happens in tumor cells leading to tumor cell lysis and activating a specific T-cell driven immune response. For this reason, a probable synergistic effect with immune checkpoints inhibition have been described. Pre-clinical studies in melanoma confirmed that T-VEC preferentially infects melanoma cells and exerts its antitumor activity through directly mediating cell death and by augmenting local and even distant immune responses. T-VEC has been assessed in monotherapy in Phase II and III clinical trials demonstrating a tolerable side-effect profile, a promising efficacy in both injected and uninjected lesions, but a mild effect at a systemic level. In fact, despite improved local disease control and a trend toward superior overall survival in respect to the comparator GM-CSF (which was injected subcutaneously daily for two weeks), responses as a single agent therapy have been uncommon in patients with visceral metastases. For this reason, T-VEC is currently being evaluated in combinations with other immune checkpoint inhibitors such as ipilimumab and pembrolizumab, with interesting confirmation of activity even systemically.

Keywords: GM-CSF; T-VEC; intratumoral immunotherapy; melanoma; oncolytic virus; talimogene laherparepvec

References

  1. Cancer. 2010 Sep 1;116(17):4139-46 - PubMed
  2. Ann Pharmacother. 2017 Aug;51(8):675-681 - PubMed
  3. J Am Coll Surg. 1999 May;188(5):522-30 - PubMed
  4. Nature. 2014 Nov 27;515(7528):568-71 - PubMed
  5. J Eur Acad Dermatol Venereol. 2001 May;15(3):218-23 - PubMed
  6. J Immunother Cancer. 2019 Jun 6;7(1):145 - PubMed
  7. Blood. 1998 Dec 1;92(11):4150-66 - PubMed
  8. Cancer Sci. 2016 Oct;107(10):1373-1379 - PubMed
  9. Ann Surg. 1974 Oct;180(4):635-43 - PubMed
  10. Ann Surg Oncol. 2015 Jul;22(7):2135-42 - PubMed
  11. Immunotherapy. 2019 Jun;11(8):705-723 - PubMed
  12. Science. 2011 Mar 25;331(6024):1565-70 - PubMed
  13. Gene Ther. 2003 Feb;10(4):292-303 - PubMed
  14. Nat Biotechnol. 2012 Jul 10;30(7):658-70 - PubMed
  15. Onco Targets Ther. 2016 Nov 16;9:7081-7093 - PubMed
  16. Biotechnol J. 2006 Feb;1(2):138-47 - PubMed
  17. J Clin Oncol. 2009 Dec 1;27(34):5763-71 - PubMed
  18. Oncogene. 2008 Oct 6;27(45):5932-43 - PubMed
  19. Cancer. 1988 Mar 15;61(6):1071-4 - PubMed
  20. Blood. 2003 Jun 15;101(12):4878-86 - PubMed
  21. J Clin Oncol. 2015 Jun 10;33(17):1974-82 - PubMed
  22. J Clin Oncol. 2016 Aug 1;34(22):2619-26 - PubMed
  23. Ann Surg Oncol. 2015 Feb;22(2):475-81 - PubMed
  24. Ann Surg Oncol. 2010 Mar;17(3):718-30 - PubMed
  25. Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264 - PubMed
  26. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  27. Cancers (Basel). 2020 Jun 26;12(6): - PubMed
  28. Oncologist. 2020 Mar;25(3):e423-e438 - PubMed
  29. Eur J Med Chem. 2020 May 1;193:112238 - PubMed
  30. Lancet Oncol. 2015 May;16(5):522-30 - PubMed
  31. Cancer Immunol Immunother. 2017 Jun;66(6):683-695 - PubMed
  32. N Engl J Med. 2017 Nov 9;377(19):1824-1835 - PubMed
  33. Biochim Biophys Acta. 2008 Apr;1785(2):217-31 - PubMed
  34. J Surg Oncol. 2014 Mar;109(4):314-9 - PubMed
  35. Cancer Discov. 2016 Aug;6(8):827-37 - PubMed
  36. Hum Gene Ther. 1999 Nov 20;10(17):2741-55 - PubMed
  37. Sci Transl Med. 2014 Mar 5;6(226):226ra32 - PubMed
  38. Ann Surg Oncol. 2018 Dec;25(13):3960-3965 - PubMed
  39. J Clin Oncol. 2018 Jun 10;36(17):1658-1667 - PubMed
  40. N Engl J Med. 2017 Nov 9;377(19):1813-1823 - PubMed
  41. J Am Acad Dermatol. 2014 Jun;70(6):979.e1-12; quiz 9912 - PubMed
  42. Immunotherapy. 2015;7(6):611-9 - PubMed
  43. N Engl J Med. 2018 May 10;378(19):1789-1801 - PubMed
  44. Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43 - PubMed
  45. Annu Rev Immunol. 2011;29:235-71 - PubMed
  46. Int J Cancer. 2019 Aug 15;145(4):974-978 - PubMed
  47. Clin Cancer Res. 2009 Dec 1;15(23):7412-20 - PubMed
  48. Cancer Res. 2005 Apr 15;65(8):3044-8 - PubMed
  49. CA Cancer J Clin. 2017 Nov;67(6):472-492 - PubMed
  50. J Am Coll Surg. 2019 Apr;228(4):644-649 - PubMed
  51. Cancer Res. 2003 Oct 1;63(19):6501-5 - PubMed
  52. J Exp Med. 2009 Feb 16;206(2):343-57 - PubMed
  53. Cell. 2017 Sep 7;170(6):1109-1119.e10 - PubMed
  54. J Surg Oncol. 2014 Mar;109(4):301-7 - PubMed
  55. Melanoma Res. 1996 Jun;6(3):247-55 - PubMed
  56. Mol Ther. 2014 Nov;22(11):1949-59 - PubMed
  57. Clin Cancer Res. 2006 Nov 15;12(22):6737-47 - PubMed
  58. Clin Cancer Res. 1999 Sep;5(9):2464-9 - PubMed
  59. Ann Surg Oncol. 2016 Dec;23(13):4169-4177 - PubMed
  60. Clin Cancer Res. 2016 Mar 1;22(5):1048-54 - PubMed
  61. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  62. Clin Cancer Res. 2017 Oct 15;23(20):6190-6202 - PubMed

Publication Types